		1614#
STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING INFORMATION DISCLOSURE STATEMENT		Docket No. 12/17/ RLL-192CIPUS
In Re Application Of: MEHTA et al.		
Serial Filing Date 10/051,784 ADEN January 17, 2002	Examiner unknown	Group Art Unit
Invention: OXAZOLIDINONE DERIVATIVES AS POTI	ENTIAL ANTIMICROBIALS	Group Art Unit
TO THE ASSISTANT COM	MISSIONER FOR PATENTS:	` &
This is a statement under the provisions of 37 CFR 1.97(e)) in the above-identified applic	cation.
Check applicable statement herebelow:		
Statement Under	r 37 CFR 1.97(e)(1)	
Each item of information contained in the accompa any communication from a foreign patent office ir months prior to the filing of the Information Disclosu	n a counterpart foreign applic	
Statement Under	r 37 CFR 1.97(e)(2)	
□ No item of information contained in the accompa communication from a foreign patent office in a cou undersigned person, after making reasonable inqui Information Disclosure Statement was known to any months prior to the filing of the Information Disclosu	unterpart foreign application, a iry, no item of information cor y individual designated in 37 (and, to the knowledge of the name of the n
Signature	Dated: November (8, 2002	2
Jayadeep R. Deshmukh Reg. No. 34,507 Ranbaxy Pharmaceuticals Inc. 600 College Road East, Suite 2100 Princeton, New Jersey 08540 Telephone: (609) 720-5608 Facsimile: (609) 514-9779	I certify that this dod November 8, 2002 class mail under 3 Assistant Commiss 20231.	of Mailing by First Class Mail cument is being deposited on with the U.S. Postal Service as first 7 C.F.R. 1.8 and is addressed to the cioner for Patents, Washington, D.C. Washington, D.C. Werson Mailing Correspondence
cc.		Christine Kenedy

cc:

Typed or Printed Name of Person Mailing Correspondence